Economic evaluation of healthcare interventions: Old and new directions

Oxford Review of Economic Policy

Volumn 32, Issue 1, 2016, Pages 102-121

  Gray, Alastair M ^a   Wilkinson, Thomas ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

Cost effectiveness analysis; Economic evaluation; Healthcare

Indexed keywords

COST-BENEFIT ANALYSIS; DISEASE TREATMENT; HEALTH CARE; HEALTH POLICY; WORLD HEALTH ORGANIZATION;

MELINDA;

EID: 84960081243     PISSN: 0266903X     EISSN: 14602121     Source Type: Journal    
DOI: 10.1093/oxrep/grv020     Document Type: Article

References (78)

1. Briggs, A. H., and O'Brien, B. J. (2001), 'The Death of Cost-minimization Analysis?', Health Economics, 10(2), 179-84.
2. Brouwer, W. B. F., Culyer, A. J., van Exel, N. J. A., and Rutten, F. F. H. (2008), 'Welfarism vs Extrawelfarism', Journal of Health Economics, 27(2), 325-38.
3. Canning, D. (2013), 'Axiomatic Foundations For Cost-effectiveness Analysis', Health Economics, 22(12), 1405-16.
4. Chisholm, D., Baltussen, R., Evans, d. B., Ginsberg, G., Lauer, J. A., Lim, S., Ortegon, M., Salomon, J., Stanciole, A., and Edejer, T. T.-T. (2012), 'What are the priorities for prevention and control of non-communicable diseases and injuries in sub-Saharan Africa and South East Asia?', BMJ, 344, e586.
5. Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P. C., and Sculpher, M. (2015), 'Methods for the Estimation of the National Institute for Health and Care Excellence Cost-effectiveness Threshold', Health Technol Assess, 19(14), 1-503, v-vi.
6. Commonwealth of Australia (1995), Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Economic Analyses, Canberra, Department of Health and Community Services.
7. Cookson, R., McCabe, C., and Tsuchiya, A. (2008), 'Public Healthcare Resource Allocation and the Rule of Rescue', Journal of Medical Ethics, 34(7).
8. Culyer, A. J. (1989), 'The Normative Economics of Health Care Finance and Provision', Oxford Review of Economic Policy, 5(1), 34.
9. Cutler, D. M., and Richardson, E. (1997), 'Measuring the Health of the US Population', Brookings Papers on Economic Activity, 0, 217-71.
10. Dakin, H., and Wordsworth, S. (2013), 'Cost-minimisation Analysis versus Cost-effectiveness Analysis, Revisited', Health Economics, 22(1), 22-34.
11. Dakin, H., Devlin, N., Feng, Y., Rice, N., O'Neill, P., and Parkin, D. (2014), 'The Influence of Cost-effectiveness and Other Factors on Nice Decisions', Health Economics, 23 September.
12. Deaton, A. (2009), 'Instruments of Development: Randomization in the Tropics, and the Search for the Elusive Keys to Economic Development', NBER Working Paper No. 14690, Cambridge, MA, National Bureau of Economic Research.
13. Detsky, A. S. (1993), 'Guidelines for Economic Analysis of Pharmaceutical Products: A Draft Document for Ontario and Canada', Pharmacoeconomics, 3(5), 354-61.
14. Devlin, N., and Parkin, D. (2004), 'Does NICE have a Cost-effectiveness Threshold and What Other Factors Influence its Decisions? A Binary Choice Analysis', Health Economics, 13(5), 437-52.
15. Drummond, M. F., and Jefferson, T. O. (1996), 'Guidelines for Authors and Peer Reviewers of Economic Submissions to the BMJ', British Medical Journal, 313, 275-83.
16. Drummond, M. F., Jonsson, B., and Rutten, F. (1997), 'The Role of Economic Evaluation in the Pricing and Reimbursement of Medicines', Health Policy, 40(3), 199-215.
17. Drummond, M. F., Stoddart, G. L., and Torrance, G. W. (1987), Methods for the Economic Evaluation of Health Care Programmes, Oxford, Oxford University Press.
18. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J., and Stoddart, G. L. (2005), Methods for the Economic Evaluation of Health Care Programmes, Oxford, Oxford University Press.
19. Duflo, E., and Kremer, M. (2004), 'Use of Randomization in the Evaluation of Development Effectiveness', in O. Feinstein, G. K. Ingram and G. K. Pitman (eds), Evaluating Development Effectiveness (World Bank Series on Development and Evaluation, volume 7), New Brunswick, NJ, Transaction Publishers, 205-32.
20. Edejer, T. T.-T., Baltussen, R., Adam, T., Hutubessy, R., Acharya, A., Evans, D. B., and Murrary, C. J. L. (2003), Making Choices in Health: WHO Guide to Cost-effectiveness Analysis, Geneva, World Health Organization.
21. Elixhauser, A. (1993), 'Health Care Cost-Benefit and Cost-effectiveness Analysis (CBA/CEA) from 1979 to 1990: A Bibliography', Medical Care, 31, JS1-JS141.
22. Elixhauser, A., Halpern, M., Schmier, J., and Luce, B. R. (1998), 'Health Care CBA and CEA from 1991 to 1996: An Updated Bibliography', Medical Care, 36(5 Suppl), MS1-147.
23. Evans, D. B., Edejer, T. T.-T., Adam, T., and Lim, S. S. (2005), 'Methods to Assess the Costs and Health Effects of Interventions for Improving Health in Developing Countries', BMJ, 331(7525), 1137-40.
24. Gafni, A., and Birch, S., (1993), 'Guidelines for the Adoption of New Technologies: A Prescription for Uncontrolled Growth in Expenditures and How to Avoid the Problem', CMAJ, 148(6), 913-17.
25. Garber, A. M., and Phelps, C. E. (1997), 'Economic Foundations of Cost-effectiveness Analysis', Journal of Health Economics, 16, 1-31.
26. George, B., Harris, A., and Mitchell, A. (2001), 'Cost Effectiveness Analysis and the Consistency of Decision Making-Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996)', PharmacoEconomics, 19(11), 1103-9.
27. Gold, M. R., Siegel, J. E., Russel, L. B., and Weinstein, M. C. (1996), Cost-effectiveness in Health and Medicine, New York, Oxford University Press.
28. Harris, A., and Bulfone, L. (2004), 'Getting Value for Money: The Australian Experience', in T. S. Jost (ed.), Health Care Coverage Determinations: An International Comparative Study, McGraw-Hill International.
29. Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., and Weissert, W. G. (2000), 'Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard', Medical Decision Making, 20(3), 332-42.
30. Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., Loder, E., and Force, C. T. (2013), 'Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement', BMJ, 346, f1049.
31. Hutubessy, R. C., Chisholm, D., and Edejer, T. T.-T. (2003), 'Generalized Cost-effectiveness Analysis for National-level Priority-setting in the Health Sector', Cost Eff Resour Alloc, 1(1), 8.
32. Hutubessy, R. C., Baltussen, R. M., Edejer, T. T.-T., and Evans, D. B. (2002), 'Generalised Cost-effectiveness Analysis: An Aid to Decision Making in Health', Appl Health Econ Health Policy, 1(2), 89-95.
33. Imbens, G. W. (2009), 'Better LATE than Nothing: Some Comments on Deaton (2009) and Heckman and Urzua (2009)', NBER Working Paper No. 14896, Cambridge, MA, National Bureau of Economic Research.
34. Jamison, D. T., Mosley, H. W., Measham, A. R., and Bobadilla, J. L. (eds) (1993), Disease Control Priorities in Developing Countries, Washington, DC, World Bank.
35. Jonsen, A. R. (1986), 'Bentham in a Box: Technology Assessment and Health Care Allocation', Law, Medicine & Health Care, 14(3-4), 172-4.
36. Kaplan, R. M., and Bush, J. W. (1982), 'Health-related Quality of Life Measurement for Evaluation Research and Policy Analysis', Health Psychology, 1(1), 61-80.
37. Kim, S.-Y., and Goldie, S. J. (2008), 'Cost-effectiveness Analyses of Vaccination Programmes', Pharmacoeconomics, 26(3), 191-215.
38. Klarman, H. E. (1982), 'The Road to Cost-effectiveness Analysis', Milbank Memorial Fund Quarterly: Health and Society, 60(4), 585-603.
39. Kumaranayake, L., and Walker, D. (2002), 'Cost-effectiveness Analysis and Priority Setting: Global Approach without Local Meaning?', ch. 8 in K. Lee, K. Buse, and S. Fustukian (eds), Health Policy in a Globalising World, Cambridge, Cambridge University Press, 140-56.
40. Laupacis, A., Feeny, D., Detsky, A. S., and Tugwell, P. X. (1992), 'How Attractive Does a New Technology have to be to Warrant Adoption and Utilization? Tentative Guidelines for Using Clinical and Economic Evaluations', CMAJ, 146(4), 473-81.
41. Linley, W. G., and Hughes, D. A. (2013), 'Societal Views on NICE, Cancer Drugs Fund and Valuebased Pricing Criteria for Prioritising Medicines: A Cross-sectional Survey of 4118 Adults in Great Britain', Health Economics, 22(8), 948-64.
42. McCabe, C., Claxton, K., and Culyer, A. J. (2008), 'The NICE Cost-effectiveness Threshold-What it is and What that Means', PharmacoEconomics, 26(9), 733-44.
43. Martin, S., Rice, N., and Smith, P. C. (2008), 'Does Health Care Spending Improve Health Outcomes? Evidence from English Programme Budgeting Data', Journal of Health Economics, 27(4), 826-42.
44. Mason, H., Jones-Lee, M., and Donaldson, C. (2009), 'Modelling the Monetary Value of A QALY: A New Approach Based on UK Data', Health Economics, 18(8), 933-50.
45. Meacock, R., Kristensen, S. R., and Sutton, M. (2014), 'The Cost-effectiveness of Using Financial Incentives to Improve Provider Quality: A Framework and Application', Health Economics, 23(1), 1-13.
46. Ministry of Public Health, Thailand (2012), 'Health Intervention and Technology Assessment Program. Health Technology Assessment Process Guidelines', available at http://www.hitap.net/system/files/health_technology_assessment_process_guidelines_english_finalversion_01march2012.pdf
47. Murphy, K. M., and Topel, R. H. (2006), 'The Value of Health and Longevity', Journal of Political Economy, 114(5), 871-904.
48. Murray, C. J., Evans, D. B., Acharya, A., and Baltussen, R. M. (2000), 'Development of WHO Guidelines on Generalized Cost-effectiveness Analysis', Health Economics, 9(3), 235-51.
49. Nadler, E., Eckert, B., and Neumann, P. J. (2006), 'Do Oncologists Believe New Cancer Drugs Offer Good Value?', Oncologist, 11(2), 90-5.
50. Neumann, P. J., Sandberg, E. A., Bell, C. M., Stone, P. W., and Chapman, R. H. (2000), 'Are Pharmaceuticals Cost-effective? A Review of the Evidence', Health Affairs, 19(2), 92-109.
51. NICE (2009), 'Appraising Life Extending, End of Life Treatments. Supplementary Advice to the Appraisal Committees', Process and Methods Guides, London, National Institute for Health and Care Excellence.
52. NICE (2013), 'Guide to the Methods of Technology Appraisal 2013', Process and Methods Guides, London, National Institute for Health and Care Excellence.
53. NICE International (2014), 'Methods for Economic Evaluation Project (MEEP) Final Report', London, Bill & Melinda Gates Foundation, NICE International, the Health Intervention and Technology Assessment Program (Thailand), and the University of York, Centre for Health Economics.
54. Oregon Health Services Commission (1991), 'Oregon Medicaid Priority Setting Project', Portland, OR, Oregon State Government.
55. Pearce, D. W., and Nash, C. A. (1981), The Social Appraisal of Projects: A Text in Cost-Benefit Analysis, London, Palgrave Macmillan.
56. Pennington, M., Baker, R., Brouwer, W., Mason, H., Hansen, D. G., Robinson, A., Donaldson, C., and the EuroVaQ Team (2015), 'Comparing WTP Values of Different Types of QALY Gain Elicited from the General Public', Health Economics, 24(3), 280-93.
57. Philips, Z., Bojke, L., Sculpher, M., Claxton, K., and Golder, S. (2006), 'Good Practice Guidelines for Decision-analytic Modelling in Health Technology Assessment-A Review and Consolidation of Quality Assessment', PharmacoEconomics, 24(4), 355-71.
58. Philipson, T. (2000), 'Economic Epidemiology and Infectious Diseases', ch. 33 in J. C. Anthony and P. N. Joseph (eds), Handbook of Health Economics Volume 1, Part B, 1761-99, Elsevier.
59. Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., and Sullivan, S. D. (2015), 'Cost-effectiveness Analysis Alongside Clinical Trials II-An ISPOR Good Research Practices Task Force Report', Value Health, 18(2), 161-72.
60. Rawlins, M. D. (1999), 'In Pursuit of Quality: The National Institute for Clinical Excellence', The Lancet, 353(9158), 1079-82.
61. Rawlins, M. D., Culyer, A. J. (2004), 'National Institute for Clinical Excellence and its Value Judgments', British Medical Journal, 329(7459), 224-7.
62. Salomon, J. A., Vos, T., Hogan, D. R., Gagnon, M., Naghavi, M., Mokdad, A., et al. (2012), 'Common Values in Assessing Health Outcomes from Disease and Injury: Disability Weights Measurement Study for the Global Burden of Disease Study 2010', The Lancet, 380(9859), 2129-43.
63. Santatiwongchai, B., Chantarastapornchit, V., Wilkinson, T., Thiboonboon, K., Rattanavipapong, W., Walker, D. G., Chalkidou, K., and Teerawattananon, Y. (2015), 'Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development', PLoS One, 10(5), e0123853.
64. Sculpher, M. J., Claxton, K., Drummond, M., and McCabe, C. (2006), 'Whither Trial-based Economic Evaluation for Health Care Decision Making?', Health Economics, 15(7), 677-87.
65. Sendi, P., Gafni, A., and Birch, S. (2002), 'Opportunity Costs and Uncertainty in the Economic Evaluation of Health Care Interventions', Health Economics, 11(1), 23-31.
66. Shillcutt, S., Walker, D., Goodman, C., and Mills, A. (2009), 'Cost-effectivess in Low- and Middleincome Countries: A Review of the Debates Surrounding Decision Rules', Pharmacoeconomics, 27(11), 903-17.
67. Stephens, D. S. (2008), 'Vaccines for the Unvaccinated: Protecting the Herd', Journal of Infectious Diseases, 197(5), 643-5.
68. Torrance, G. W. (1976), 'Toward a Utility Theory Foundation for Health Status Index Models', Health Services Research, 11, 439-69.
69. Viscusi, W. K., Huber, J., and Bell, J. (2014), 'Assessing Whether There is a Cancer Premium for the Value of a Statistical Life', Health Economics, 23(4), 384396.
70. Warner, K. E., and Hutton, R. C. (1980), 'Cost-Benefit and Cost-effectiveness Analysis in Health Care-Growth and Composition of the Literature', Medical Care, 18(11), 1069-84.
71. Weinstein, M. C. (2006), 'Recent Developments in Decision-analytic Modelling for Economic Evaluation', Pharmacoeconomics, 24(11), 1043-53.
72. Weinstein, M. C., Manning, W. G. (1997), 'Theoretical Issues in Cost-effectiveness Analysis', Journal of Health Economics, 16(1), 121-8.
73. Weinstein, M. C., Stason, W. B. (1977), 'Foundations of Cost-effectiveness Analysis for Health and Medical Practices', New England Journal of Medicine, 296(13), 716-21.
74. Weisbrod, B. A. (1971), 'Costs and Benefits of Medical Research-Case Study of Poliomyelitis', Journal of Political Economy, 79(3), 527-44.
75. WHO Commission on Macroeconomics and Health (2001), Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health, J. Sachs, Geneva, World Health Organization.
76. Whyte, P., and Hall, C. (2013), 'Working Paper 6: The Role of Health Technology Assessment in Medicine Pricing and Reimbursement', WHO/HAI Project on Medicine Prices and Availability Review Series on Pharmaceutical Pricing Policies and Interventions. Australia.
77. Williams, A. (2004), What Could be Nicer than NICE?, London, Office of Health Economics.
78. World Bank (1993), World Development Report 1993: Investing in Health, New York, Oxford University Press.